维A酸受体β在食管鳞癌组织中的表达及其与化疗疗效的关系  

The relationship between retinoic acid receptor-β expression and chemotherapy response in esophageal squamous cell carcinoma

作　　者：路太英[1] 李文斌[1] 李鑫[1] 王留兴[1] 王瑞林[1] 张岚[2] 陆士新[3] 樊青霞[1] 

机构地区：[1]郑州大学第一附属医院肿瘤科,450052 [2]郑州大学第一附属医院病理科,450052 [3]中国医学科学院北京协和医学院肿瘤研究所

出　　处：《中华内科杂志》2010年第10期848-850,共3页Chinese Journal of Internal Medicine

基　　金：河南省自然科学基金资助项目（611040600）

摘　　要：目的 观察维A酸受体β（RAR-β）在食管鳞癌中的表达及其与化疗疗效的关系.方法 52例中晚期食管鳞癌患者给予以顺铂（DDP）＋5-氟尿嘧啶（5-FU）为基础的联合方案化疗.DDP 80 mg/m2,分为5 d静脉滴注;5-FU每日375 mg/m2,第1～5天静脉滴注,21 d为1个周期.应用免疫组化法检测RAR-β在食管鳞癌组织中的表达.以50例正常食管黏膜作为对照.结果 RAR-β阳性染色主要位于细胞质和（或）胞核,食管鳞癌组织中RAR-β阳性率（61.5%,32/52）明显低于正常食管黏膜组织（92.0%,46/50）,P＜0.05.52例食管鳞癌患者共完成228个化疗周期,总有效率71.2%,RAR-β阳性表达者有效率84.4%（27/32）,显著高于RAR-β阴性表达者的50.0%（10/20）,P＜0.05.RAR-β阳性表达者中位疾病进展时间为5.9个月,中位生存时间12.1个月,2年生存率56.7%;而RAR-β阴性表达者中位疾病进展时间为2.1个月,中位生存时间5.8个月,2年生存率32.9%,两组间比较差异均有统计学意义（P＜0.05）.结论 免疫组化法检测RAR-β的表达可作为临床上预测食管癌化疗疗效及预后的指标之一,同时RAR-β可能成为食管癌治疗的靶点.Objective To observe the relationship between expression of retinoic acid receptor-β （RAR-β） in esophageal squamous cell carcinoma （ESCC） and chemotherapy response. Methods Fifty-two cases advanced ESCC patients treated by DDP and 5-FU, DDP 80 mg/m2, divided into 5 days;5-FU 375 mg/m2, dl-5. Immunohistochemistry was used to exmine the expression of RAR-β in ESCC. Fifty cases normal esophageal tissue were used as controls. Results RAR-β immunoreactivity was recognizd in both cytoplasm and nucleus, RAR-β positive rate was lower in ESCC compared with normal tissue （61.5%vs 92% ,P ＜0. 05 ）. The 52 cases ESCC patients were treated 228 chemotherapy cycles, the overall response rate （OR） was 71.2%. The OR in RAR-β positive patients was 84. 4% （27/32）, significant higher than RAR-β negative patients 50. 0% （ 10/20 ） （ P ＜ 0. 05 ）. The time-to-progression （ TTP ） for RAR-β positive patients was 5.9 months, the median survival period was 12. 1 months, 2 years survival rate was 56. 7%;whereas TTP for RAR-β negative patients was 2. 1 months, the median survival period was 5.8 months,2 years survival rate was 32. 9%. There was signifcant difference between the 2 groups （ P ＜ 0. 05 ） .Conclusion RAR-β protein expression by immunohistochemistry may be a useful indicator to predict the chemotherapy response and clinical outcome for ESCC, meanwhile it may be an avenue for target therapy.

关 键 词：食管肿瘤 受体 维甲酸 药物疗法 

分 类 号：R686[医药卫生—骨科学]